Healthcare provider profile · identity verified

Andre' Blair Smith, MD

Family Practice · LANSING, MI · NPI 1417920463

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	275	25
Omeprazole	Omeprazole	237	37
Atorvastatin Calcium	Atorvastatin Calcium	222	33
Levothyroxine Sodium	Levothyroxine Sodium	185	26
Amlodipine Besylate	Amlodipine Besylate	175	27
Lisinopril	Lisinopril	157	28
Gabapentin	Gabapentin	123	19
Donepezil Hcl	Donepezil Hcl	121	17
Metoprolol Tartrate	Metoprolol Tartrate	121	15
Metoprolol Succinate	Metoprolol Succinate	119	18
Eliquis	Apixaban	112	19
Losartan Potassium	Losartan Potassium	109	17
Tamsulosin Hcl	Tamsulosin Hcl	106	15
Montelukast Sodium	Montelukast Sodium	102	16
Simvastatin	Simvastatin	101	17
Glipizide Er	Glipizide	90	14
Metformin Hcl	Metformin Hcl	86	13
Finasteride	Finasteride	85	12
Sertraline Hcl	Sertraline Hcl	84	15
Quetiapine Fumarate	Quetiapine Fumarate	80	12
Escitalopram Oxalate	Escitalopram Oxalate	79	17
Furosemide	Furosemide	79	13
Levetiracetam	Levetiracetam	78	11
Trazodone Hcl	Trazodone Hcl	72	13
Albuterol Sulfate Hfa	Albuterol Sulfate	71	19
Carvedilol	Carvedilol	69	12
Myrbetriq	Mirabegron	68	suppressed
Hydralazine Hcl	Hydralazine Hcl	62	11
Clopidogrel	Clopidogrel Bisulfate	61	11
Potassium Chloride	Potassium Chloride	61	17
Buspirone Hcl	Buspirone Hcl	60	13
Diclofenac Sodium	Diclofenac Sodium	60	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	60	suppressed
Tramadol Hcl	Tramadol Hcl	56	suppressed
Atenolol	Atenolol	52	suppressed
Baclofen	Baclofen	50	11
Azithromycin	Azithromycin	49	33
Duloxetine Hcl	Duloxetine Hcl	49	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	48	suppressed
Allopurinol	Allopurinol	47	suppressed
Aripiprazole	Aripiprazole	47	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	46	suppressed
Januvia	Sitagliptin Phosphate	44	suppressed
Memantine Hcl Er	Memantine Hcl	41	suppressed
Meloxicam	Meloxicam	40	suppressed
Mirtazapine	Mirtazapine	40	suppressed
Farxiga	Dapagliflozin Propanediol	38	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	35	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	34	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	34	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	33	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	33	27
Xarelto	Rivaroxaban	33	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	32	suppressed
Spironolactone	Spironolactone	32	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	31	suppressed
Carbamazepine Er	Carbamazepine	28	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	28	11
Fluoxetine Hcl	Fluoxetine Hcl	27	suppressed
Pregabalin	Pregabalin	27	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	26	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	26	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	25	suppressed
Trulicity	Dulaglutide	25	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	24	suppressed
Memantine Hcl	Memantine Hcl	24	suppressed
Famotidine	Famotidine	23	suppressed
Naproxen	Naproxen	23	suppressed
Paroxetine Hcl	Paroxetine Hcl	22	suppressed
Bumetanide	Bumetanide	21	suppressed
Carbidopa-Levodopa Er	Carbidopa/Levodopa	21	suppressed
Alprazolam	Alprazolam	20	suppressed
Primidone	Primidone	19	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	19	suppressed
Ventolin Hfa	Albuterol Sulfate	19	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	18	suppressed
Levofloxacin	Levofloxacin	18	13
Oxybutynin Chloride	Oxybutynin Chloride	18	suppressed
Ezetimibe	Ezetimibe	17	suppressed
Ibandronate Sodium	Ibandronate Sodium	17	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	17	suppressed
Clonidine Hcl	Clonidine Hcl	16	suppressed
Fluticasone Propionate	Fluticasone Propionate	16	suppressed
Nebivolol Hcl	Nebivolol Hcl	16	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	16	suppressed
Alendronate Sodium	Alendronate Sodium	15	suppressed
Cephalexin	Cephalexin	15	suppressed
Folic Acid	Folic Acid	15	suppressed
Hydrocortisone	Hydrocortisone	15	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	15	suppressed
Mupirocin	Mupirocin	15	13
Risperidone	Risperidone	15	suppressed
Erythromycin	Erythromycin Base	14	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	14	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	14	suppressed
Novolin N Flexpen	Insulin Nph Human Isophane	14	suppressed
Raloxifene Hcl	Raloxifene Hcl	14	suppressed
Selegiline Hcl	Selegiline Hcl	14	suppressed
Topiramate	Topiramate	14	suppressed
Balsalazide Disodium	Balsalazide Disodium	13	suppressed
Bupropion Hcl Sr	Bupropion Hcl	13	suppressed
Digoxin	Digoxin	13	suppressed
Ketoconazole	Ketoconazole	13	suppressed
Lamotrigine	Lamotrigine	13	suppressed
Clonidine	Clonidine	12	suppressed
Divalproex Sodium	Divalproex Sodium	12	suppressed
Phenobarbital	Phenobarbital	12	suppressed
Arnuity Ellipta	Fluticasone Furoate	11	suppressed
Brilinta	Ticagrelor	11	suppressed
Creon	Lipase/Protease/Amylase	11	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	11	suppressed
Fludrocortisone Acetate	Fludrocortisone Acetate	11	suppressed
Fosinopril-Hydrochlorothiazide	Fosinopril/Hydrochlorothiazide	11	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	11	suppressed
Metformin Hcl Er	Metformin Hcl	11	suppressed
Zafirlukast	Zafirlukast	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error